Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000950170-24-009505

Chief Executive Officer sold 50,000 shares at an average $60.51 ($3,025,573)

  • Chief Executive Officer acquired 50,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2024-01-29 Option exercise 10b5-1 +50,000 $19.12 $956,000 237,377 D
Kulkarni Samarth Chief Executive Officer 2024-01-29 Sale 10b5-1 −49,300 $60.50 $2,982,803 188,077 D
Kulkarni Samarth Chief Executive Officer 2024-01-29 Sale 10b5-1 −700 $61.10 $42,770 187,377 D
Derivatives
Kulkarni Samarth Chief Executive Officer 2024-01-29 Option exercise · Stock Option (Right to Buy) 10b5-1 −50,000 100,000 D
Open-market sales · 50,000 sh · avg $60.51 · $3,025,573
Loading xslF345X05/ownership.xml…